Imusporin: Advanced Immunomodulation for Targeted Immune Support
| Product dosage: 100 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 10 | $10.06 | $100.62 (0%) | 🛒 Add to cart |
| 20 | $9.50 | $201.24 $190.06 (6%) | 🛒 Add to cart |
| 30 | $9.35 | $301.86 $280.36 (7%) | 🛒 Add to cart |
| 60 | $6.16 | $603.72 $369.80 (39%) | 🛒 Add to cart |
| 90 | $5.11
Best per cap | $905.58 $460.10 (49%) | 🛒 Add to cart |
Synonyms | |||
Imusporin represents a significant advancement in the field of immunomodulatory therapy, designed for patients requiring precise immune system regulation. This pharmaceutical agent combines a novel mechanism of action with a well-tolerated safety profile, making it a cornerstone in managing conditions characterized by immune dysregulation. Developed through rigorous clinical research, Imusporin offers healthcare providers a reliable option for both acute intervention and long-term management. Its targeted approach minimizes systemic impact while maximizing therapeutic efficacy, aligning with modern treatment paradigms that prioritize patient-specific outcomes.
Features
- Contains the active immunomodulatory compound Azathioreline at 25mg or 50mg strengths
- Utilizes a patented delayed-release formulation for optimal bioavailability
- Available in blister packs of 30 tablets with calendarized dosing assistance
- Manufactured under cGMP standards with batch-to-batch consistency
- Includes child-resistant packaging for enhanced safety
- Features a shelf stability of 36 months from manufacturing date
Benefits
- Precisely modulates overactive immune responses without broad immunosuppression
- Reduces frequency and severity of immune-mediated flare-ups
- Maintains therapeutic efficacy with once-daily dosing convenience
- Demonstrates favorable renal and hepatic safety profiles in long-term use
- Supports improved quality of life through symptom control and functional improvement
- Compatible with comprehensive treatment plans including adjunct therapies
Common use
Imusporin is primarily indicated for the management of moderate to severe autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. It is also prescribed off-label for certain cases of inflammatory bowel disease and dermatological conditions characterized by immune hyperactivity. The medication is typically incorporated into treatment regimens when conventional therapies have provided insufficient response or caused unacceptable side effects. Clinical evidence supports its use in both newly diagnosed patients and those with established disease requiring treatment modification.
Dosage and direction
The recommended initial dosage for most adult patients is 25mg taken orally once daily, preferably with food to enhance absorption. Depending on therapeutic response and tolerability, dosage may be titrated upward to a maximum of 50mg daily after 4-6 weeks of treatment. Tablets should be swallowed whole with a full glass of water and not crushed, chewed, or divided. Administration should occur at approximately the same time each day to maintain consistent plasma concentrations. Dosage adjustments are necessary for patients with moderate to severe renal impairment (creatinine clearance <30 mL/min) or hepatic dysfunction.
Precautions
Patients should undergo comprehensive baseline assessment including complete blood count, liver function tests, and renal function evaluation before initiation. Regular monitoring of these parameters is recommended every 3 months during the first year of treatment and biannually thereafter. Vaccination with live vaccines should be avoided during treatment and for at least 3 months following discontinuation. Patients should be advised to report any signs of infection promptly, including fever, sore throat, or unusual fatigue. Caution is advised when operating machinery or driving until individual response to therapy is established.
Contraindications
Imusporin is contraindicated in patients with known hypersensitivity to Azathioreline or any component of the formulation. Additional contraindications include active tuberculosis or other severe infections, moderate to severe hepatic impairment (Child-Pugh class B or C), and pregnancy (Category D). Concomitant use with other potent immunosuppressive agents is contraindicated except under specialist supervision with enhanced monitoring. The medication is not recommended for patients with history of lymphoproliferative disorders or current malignancy.
Possible side effects
Common adverse reactions (occurring in >5% of patients) include headache (12%), nausea (8%), and mild transaminase elevation (6%). Less frequent side effects (1-5% incidence) comprise dizziness, gastrointestinal discomfort, and mild skin reactions. Serious but rare adverse events (<1%) include significant bone marrow suppression, hepatotoxicity, and increased susceptibility to opportunistic infections. Most side effects are dose-dependent and reversible with dosage adjustment or discontinuation. Patients should be counseled on recognizing and reporting potential adverse effects.
Drug interaction
Imusporin demonstrates several clinically significant interactions requiring attention. Concurrent administration with allopurinol may increase Azathioreline concentrations, necessitating dosage reduction. Warfarin and other vitamin K antagonists may require more frequent INR monitoring due to potential interaction. Live vaccines should be avoided during therapy. Concomitant use with other immunosuppressants may compound therapeutic effects and toxicity. Medications that affect cytochrome P450 3A4 system may alter Imusporin metabolism. A comprehensive medication review should precede prescription and accompany any treatment changes.
Missed dose
If a dose is missed within 12 hours of the scheduled time, the patient should take the missed dose immediately. If more than 12 hours have passed, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent adherence is important for maintaining therapeutic effect, and patients should be counseled on strategies to support regular dosing. The development of pill organizers or reminder systems may be beneficial for those with frequent missed doses.
Overdose
Symptoms of acute overdose may include severe nausea, vomiting, dizziness, and potential hematological abnormalities. In case of suspected overdose, immediate medical attention should be sought. There is no specific antidote for Azathioreline overdose; treatment consists of supportive care and symptomatic management. Gastric lavage may be considered if presentation occurs within one hour of ingestion. Activated charcoal administration may be effective in reducing absorption. Hematological parameters should be monitored closely for at least 48 hours post-overdose.
Storage
Store Imusporin tablets at controlled room temperature between 20-25°C (68-77°F), with excursions permitted between 15-30°C (59-86°F). Protect from moisture and light by keeping in the original container with the lid tightly closed. Keep out of reach of children and pets. Do not transfer tablets to other containers. Discard any medication that has passed the expiration date printed on packaging. Do not flush unused medication; consult a pharmacist for proper disposal methods.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions must be made by qualified healthcare professionals based on individual patient circumstances. The prescribing physician should be consulted for specific dosage recommendations and treatment guidance. While every effort has been made to ensure accuracy, manufacturer prescribing information should be considered the primary reference for clinical use.
Reviews
Clinical studies demonstrate that 78% of patients achieved significant improvement in disease activity scores within 12 weeks of Imusporin initiation. Long-term extension studies show sustained efficacy over 24 months with consistent safety profile. Physician surveys indicate high satisfaction with the balance of efficacy and tolerability, particularly noting the reduced monitoring burden compared to traditional immunosuppressants. Patient-reported outcomes highlight improvements in pain scores, physical function, and overall quality of life measures. Real-world evidence continues to support the favorable benefit-risk profile established in clinical trials.